News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
ReNeuron Says Initial Tests On Stroke Treatment OK
November 18, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Stem-cell firm ReNeuron Group Plc (RENE.L: Quote, Profile, Research) said on Friday that initial tests on its stroke treatment ReNOO1 found it did not form tumours, a factor it says is key for approval to carry out human trials.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Europe
MORE ON THIS TOPIC
Spinal muscular atrophy
Roche Ends Run for Muscular Atrophy Drug, Leaving Door Open for Competitors
March 20, 2026
·
2 min read
·
Tristan Manalac
FDA
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure
March 19, 2026
·
2 min read
·
Annalee Armstrong
Diabetes
Lilly Builds Differentiated Profile for Triple-G Agonist With Late-Stage Diabetes Data
March 19, 2026
·
2 min read
·
Tristan Manalac
Insights
Inside the Race to Build the Next Generation of AI Drug Discovery Platforms
March 19, 2026
·
1 min read
·
Jennifer C. Smith-Parker
